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RocaglatesIdentification of novel drug targets and affordable therapeutic agents remains a high priority in the fight against
chronic hepatitis C virus (HCV) infection. Here, we report that the cellular proteins prohibitin 1 (PHB1) and 2
(PHB2) are pan-genotypic HCV entry factors functioning at a post-binding step. While predominantly found in
mitochondria, PHBs localize to the plasma membrane of hepatocytes through their transmembrane domains
and interact with both EGFR and CRaf. Targeting PHB by rocaglamide (Roc-A), a natural product that binds
PHB1 and 2, reduced cell surface PHB1 and 2, disrupted PHB-CRaf interaction, and inhibited HCV entry at low
nanomolar concentrations. A structure-activity analysis of 32 synthetic Roc-A analogs indicated that the chiral,
racemic version of aglaroxin C, a natural product biosynthetically related to Roc-A, displayed improved potency
and therapeutic index against HCV infection. This study reveals a new class of HCV entry inhibitors that target the
PHB1/2-CRaf pathway.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hepatitis C virus (HCV) is an important human pathogen that pri-
marily infects human hepatocytes and causes chronic liver diseases
(Kontorinis et al., 2004). It is undeniable that recently approved
direct-acting antiviral (DAA)-containing regimens have radically
changed the paradigm of chronic HCV treatment. However, it remains
unclearwhether DAAs fully prevent pathology or restore normal immu-
nity. Moreover, with continuous and expanded usage of DAAs, HCV is
expected to become progressively more drug resistant, thereby eroding
the efficacy of DAAs (Pawlotsky et al., 2015). Lastly, most DAAs are
hardly affordable to patients in resource-limited countries. For these
reasons, druggable host targets and new lead compounds are highly
desirable.HCVcc, cell culture grown HCV;
e proteins; VSV-Gpp, HIV parti-
protein G; MOI, multiplicity of
ngunya virus envelope proteins.
bu.edu (J.A. Porco),
. This is an open access article underHCV entry is a multifaceted target for intervention. HCV encodes ten
viral proteins to complete its life cycle. Viral glycoproteins E1 and E2 to-
gether form spikes on the viral envelope, which then engage with cell
surface molecules (Lindenbach et al., 2005; Kato et al., 2005; Zhang
et al., 2004; Cormier et al., 2004; Bartosch et al., 2003; Petracca et al.,
2000) and trigger the endocytosis of the viral particle (Meertens et al.,
2006; Hsu et al., 2003). In addition, E2 interacts with HCV nonstructural
protein 2 (NS2) and plays an important role in virus morphogenesis
(Selby et al., 1994). Recent advances have suggested thatHCV enters he-
patocytes in a step-wise fashion by utilizingmultiple cellularmembrane
proteins, including CD81 (Pileri et al., 1998), scavenger receptor BI (SR-
BI) (Scarselli et al., 2002), claudin-1 (CLDN1) (Evans et al., 2007),
occludin (OCLN) (Liu et al., 2009; Ploss et al., 2009), epidermal growth
factor receptor (EGFR) (Lupberger et al., 2011), and cholesterol-
uptake receptor Niemann-Pick C1-like 1 (NPC1L1) (Sainz et al., 2012).
Zona and coworkers further reported that the GTPase HRas acts as a sig-
nal transducer for EGFR-mediatedHCV entry by regulating lateralmem-
brane diffusion of CD81 which then enables tetraspanin receptor
complex assembly (Zona et al., 2013).
In an attempt to identify novel cellular targets for antiviral develop-
ment, we found that the cellular proteins prohibitin (PHB) 1 and 2 asso-
ciate with HCV E2 in infected human hepatoma cells. We furtherthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1601S. Liu et al. / EBioMedicine 2 (2015) 1600–1606demonstrated that PHBs mediate HCV entry at a post-binding step
through their interaction with the signaling molecule CRaf. Blocking
PHB-CRaf interactions with the natural product rocaglamide (Roc-A)
potently inhibitedHCV entry, and the biosynthetically-related rocaglate
natural product aglaroxin C displayed both improved potency and
therapeutic index.
2. Materials and Methods
Full experimental methods are provided in detail in the Supplemental
Information.
2.1. Immunofluorescence Staining and Confocal Microscopy
Detailed procedures have been published (Yang et al., 2008). In brief,
cells were stained with mitotracker red (1:10,000) at 37 °C for 15 min
and then fixed in−20 °C cold methanol for 5 min. Antibody dilutions
are: anti-PHB1 (Santa Cruz, E-5 clone, 1:200), anti-PHB2 (Millipore,
Cat No. 07–234, 1:200). Secondary antibodies were Alexa Fluor 488 or
568 Goat Anti-Mouse or Rabbit IgG (Life technologies 1:1000). Images
were captured by a Zeiss LSM 700 laser scanning microscope.
2.2. HCV E1E2-Mediated Cell–Cell Fusion Assay
Detailed protocols have been published (Si et al., 2012). In brief,
Huh7.5.1 cells were transfected with si-CTRL (control siRNA), or si-
PHB1, or si-PHB2, and Stop-Luc construct which contains a firefly lucif-
erase reporter gene whose transcription is prevented by a Stop cassette
flanked by LoxP sites. 48 h post-transfection, these recipient cells
were mixed at a 1:1 ratio with 293T-CLDN1 cells expressing Cre and
HCV E1E2 (H77, genotype 1a) (donor cells) to initiate cell–cell fusion.
Luciferase activity was measured 24 h thereafter.
2.3. Cell Surface Biotinylation Assay
Huh7.5.1 cells from four 150 mm plates were treated with DMSO,
Roc-A (20 nM), or infected by HCVcc. 48 h post-transfection, cells
were washed three times with ice-cold PBS and resuspended in PBS at
a density of 25 × 106 cells/ml. Freshly prepared Sulfo-NHS-SS-biotin
(Pierce) was added to the cells (final concentration 0.5 μg/ml) and
allowed to incubate at 4 °C for 30 min. Cells were then washed three
times with ice-cold PBS. 25 mM Tris (pH 8.0) was added in the initial
wash to quench any non-reacted biotin reagent. Following cell lysis in
RIPA buffer (50 mM Tris–HCl [pH 7.5], 150 mM NaCl, 1% NP-40, 0.25%
sodium deoxycholate, 1 mM EDTA, 2 mM Na3VO4 and Pierce protease
inhibitor cocktail), lysates were cleared by centrifugation at 13,000 ×g
for 15 min at 4 °C. The cleared lysates were used for immunoprecipita-
tion using a 1:1 mixture of Streptavidin beads (Pierce). Beads were
washed three times with RIPA buffer, and bound proteins were eluted
by boiling the samples in SDS-PAGE sample buffer and then resolved
on 9% SDS-PAGE. Biotinylated proteins were detected by anti-PHB1
and anti-PHB2 antibodies.
2.4. Cytotoxicity/Cell Viability Assay
PHHs (105 per well) were treated with Roc-A or DMSO at various
concentrations for 48 h in 48-well plates. The numbers of viable cells in
culture were determined using the CellTiter-Glo Cell Viability Lumines-
cent Assay kit according to the manufacturer's instruction (Promega).
2.5. Statistical Analysis
Bar graphswere plotted to showmean± standard deviation (SD) of
at least two independent experiments. Statistical analyses were per-
formed using Graphpad Prism 5. A p value of b0.05 in the Student's
test was considered statistically significant.2.6. Chemical Synthesis
Synthetic rocaglates and derivatives were obtained from the chemical
collection at the BU Center for Molecular Discovery (BU-CMD). Chiral, ra-
cemic rocaglates (Roche et al., 2010a, 2010b) and rocaglate hydroxamates
(Rodrigo et al., 2012) were synthesized using the reported procedures.
Chiral, non-racemic (−)-aglaroxin C and (+)-aglaroxin C were synthe-
sized using biomimetic kinetic resolution of chiral, racemic aglain ketone
precursors according to our publishedprotocol (Stone et al., 2015) follow-
ed by further chemical transformations. (−)-Roc-A, and (+)-Roc-A were
synthesized using the same protocol followed by amide formation
(Gerard et al., 2006).3. Results
3.1. PHB1 and 2 Interact with HCV E2
Wehave previously conducted a comparative proteomics analysis of
the HCV-infected human hepatoma cell line Huh7.5.1 in order to
identify HCV E2-interacting proteins. PHB1 and 2 were found to be
the most abundant proteins in the E2 complex as detected by mass
spectrometry. To validate the result, we performed immunoprecipita-
tion using lysates from cells infected with the Flag-E2 JFH1 virus and
confirmed that PHB1 and 2 co-precipitated with HCV E2 (Fig. S1A).
The PHB-E2 association does not require the presence of other viral
components as demonstrated in co-immunoprecipitation (Co-IP)
studies (Fig. S1B).3.2. PHB1 and 2 are Required for HCV Entry
PHB1 is a ubiquitously expressed protein displaying antiproliferative
activity (McClung et al., 1989). PHB2, also named repressor of estrogen
receptor activity (REA), suppresses estrogen receptor (ER)-dependent
gene activation (Montano et al., 1999). Interestingly, PHB has been im-
plicated in the entry process of dengue and chikungunya virus (CHIKV)
and also binds to HIV-1 glycoprotein and envelope proteins of white
spot syndrome virus (Lan et al., 2013; Wintachai et al., 2012;
Kuadkitkan et al., 2010; Emerson et al., 2010). To explore the role of
PHB in modulating HCV infection, we transfected Huh7.5.1 cells with
siRNA targeting PHB1 and PHB2, respectively. Reduction of endogenous
PHB1 or 2 significantly inhibited cell culture grown HCV (HCVcc) as
measured by either luciferase assays or real-time PCR quantification of
viral RNA (Fig. 1A and B). By contrast, PHB knockdown had no effect
at viral RNA levels if the infection took place first (Fig. S1C), suggesting
that PHBs are required at an early stage of HCV infection. Notably, PHB1
and PHB2 knockdown also decreased the protein levels of each other
(Fig. S1D).
We then found that PHB1 and 2 are required for HCV entry, as
silencing PHB1/2 in Huh7.5.1 cells or primary human hepatocytes
(PHHs) ablated HIV–HCV pseudotype (HCVpp) infection while hav-
ing no effect on pseudotyped virus displaying vesicular stomatitis
virus G protein (VSV-Gpp) (Fig. 1C). Furthermore, PHB knockdown
significantly reduced the infection of HCVpp-bearing glycoproteins
from various HCV genotypes (Fig. 1D). When tested in a HCV repli-
con cell line, however, knockdown of endogenous PHB1 and 2 did
not decrease viral RNA replication or protein translation (Fig. S1E
& F).
To strengthen the above findings and to exclude the off-target
effects of siRNAs, we generated Huh7.5.1 stable clones in which the
PHB1 and 2 expressions are regulated by doxycycline. PHB1 or 2 silencing
rendered these cells less susceptible toHCV infection. However, induction
of siRNA-resistant PHB1 or PHB2 restored cell susceptibility to HCVcc in-
fection (Fig. 1E and F). Altogether, our results indicate that PHB1 and 2 are
pan-genomic HCV entry factors.
Fig. 1. Endogenous PHB1 and PHB2 are required for HCV infection. (A–B) Endogenous PHB1 and 2were knocked down by siRNA transfection followed byHCVcc-Luc infection (MOI ~ 0.3).
Numbers shownbelowWestern blot gel images indicate the relative expression levels quantifiedbyOdyssey imaging system(LI-CORBiosciences). Luciferase activitywas determined72h
post-infection (A), intracellular viral RNAwas quantifiedbyRT-qPCRusing protocols described in Experimental Procedures (B). Data are shownasmean±SD, *pb 0.05. (C) Knockdownof
PHB1 and 2 inHuh7.5.1 (left) or PHHs (right)were achieved by transfecting cells with relevant siRNA for 48 h. Cells were infected byHCVpp (H77) or VSV-Gpp (MOI ~ 0.5). The percent of
infection in cells transfected with si-CTRL (control) was arbitrarily set to 100% (mean ± SD, *p b 0.05). (D) Huh7.5.1 were first transfected with siRNA targeting PHB1 and 2 and then
infected by HCVpp bearing glycoproteins derived from genotypes 1a, 2b, 3a, and 4c. (mean ± SD, *p b 0.05). (E & F) Restoration of HCV entry in PHBs knockdown cells by exogenously
expressing PHB1 & 2. Silencing PHB1 (E) or 2 (F) by siRNA in Huh7.5.1 stable clones containing a control vector (Dox-CTRL) or a siRNA-resistant PHB-Myc (Dox-PHB1 & 2) expressing
plasmid. Doxycycline was added to induce the expression of PHB-Myc. Cells were then infected by HCVcc-Luc for luciferase assay. The Western blot images were shown at the bottom
of each panel to confirm the specific induction of PHB-Myc.
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Post-Binding Step in HCV Infection
To gain insights into the roles of PHBs in HCV entry, we first ex-
amined the cellular distribution of PHB1/2. Typically found in the
inner membrane of mitochondria, PHB1 and 2 form a large
multimeric complex to stabilize newly synthesized mitochondrial
proteins (Back et al., 2002). In addition, PHB1 and 2 are reportedly
present on the plasma membrane, cytosol, and nucleus (Mishra
et al., 2005; Theiss and Sitaraman, 2011; Kim do et al., 2013;Kolonin et al., 2004). Confocal microscopy study of endogenous
PHB1 and 2 in Huh7.5 cells revealed a typical mitochondria localiza-
tion pattern, although a small portion of PHB2 appeared to traffic to
cell surface (Fig. S2A). To definitively examine if PHB1 and 2 traffic
to plasma membrane, cell surface proteins were biotinylated and
then purified using streptavidin agarose beads. Both PHB1 and 2
were detected in the pull-down product, confirming their presence
on the plasma membrane (Fig. 2A). Of note, HCV infection did not
change the amount of PHB1 and 2 that were found in the precipitates
(Fig. 2A, lane 3).
Fig. 2. PHB1 and 2 mediate HCV entry via a novel mechanism. (A) Huh7.5.1 cells were surface biotinylated as described in the Materials and Methods section. IP was done using
streptavidin agarose beads. The presence of PHB1 and PHB2 was detected by Western blotting. Lane 1, no biotin labeling; lane 2, biotin labeled; lane 3, HCVcc infected cells labeled
with biotin; lane 4, RocA (20 nM) treated cells labeled with biotin. Of note, because Roc-A treatment decreased the total cellular PHB1 and 2 (Shown in Fig. 3B), we intentionally used
twice as many cells as starting materials for the Roc-A treated group (Lane 4) in order to achieve similar amount of prohibitins in the input in comparison to the levels in other lanes.
(B) Domain organization of PHBs. (C) Surface biotinylation assay on individual PHB deletionmutants. (D) Confocal images of PHBdeletionmutants. Green, PHBmutants; Red,mitotracker.
(E), co-IP studies of Flag-E2 (F-E2) andV5-tagged PHBdeletionmutants. (F) Real-time quantification of HCV RNA bound to cells inwhich PHB1 or PHB2were knocked down. Results were
calculated as relative RNA copieswith numbers obtained from si-CTRL transfected cells set to 1 (mean± SD, *p b 0.05). (G) 293 T-CLDN1 cells expressing HCV E1E2 and Cre were fused to
Huh7.5.1 cells that were transfected with siRNA and Stop-Luc expressing plasmid. Luciferase activity was determined 24 h after mixing (mean ± SD, *p b 0.05).
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tational studies revealed that only the removal of the transmembrane do-
main (TMD) of PHBs led to the loss of cell surface localization (Fig. 2C).
Interestingly, upon removal of their C-terminal domains, PHBs preserved
both their cell surface and mitochondrial location, yet were unable to in-
teract with HCV E2 (Fig. 2D & E).
To further investigate the mechanistic action of PHB, we directly
evaluated the role of PHB on binding of HCV to the cell surface. To this
end, HCV virions were incubated with PHB knockdown cells at 4 °C
for 2 h to allow binding but not penetration. After extensive wash,
surface-bound virions were quantified by measuring the abundance of
viral RNA. Shown in Fig. 2F, the amount of viral RNA bound to PHB-
knockdown cells was comparable to that of si-CTRL cells, indicating
that PHB silencing has no effect on binding of HCV to cells. Similarly,
PHB knockdown did not have significant effect on CD81, SR-BI,
CLDN1, or OCLN expression (Fig. S2B), nor did PHBs interact with any
of these known entry factors (Fig. S2B). Lastly, we measured the HCV
E1E2-dependent fusion and found that PHB knockdown cells were
impaired in fusing with 293T cells expressing HCV E1E2 (Fig. 2G). Alto-
gether, these results suggest that PHB1 and 2 are involved in a late stage
during virus entry.
3.4. PHB1 and 2 Interact with CRaf
Co-IP studies showed that PHB1 and 2 interact with EGFR and
CRaf (Fig. S2C & D). Removal of the entire C-terminal domains of
PHB1 and 2 abolished the interaction betweenPHB and CRaf. In contrast
to a recent publication which reported that a Raf inhibitor (10 μM)
failed to block HCV infection (Diao et al., 2012), silencing CRaf expres-
sion in Huh7.5.1 cells specifically suppressed HCV entry (Fig. S2E).
Correctively, our data suggest that the PHB-CRaf pathway is critical for
HCV infection.3.5. A PHB Inhibitor, Rocaglamide A (Roc-A), Inhibits HCV Entry
Next, we asked whether targeting the PHB-CRaf pathway would
be a viable approach to block HCV infection. The natural product
rocaglamide A (Roc-A) has been shown to directly bind to PHB1
and 2 and blocks PHB-CRaf-MEK-ERK signaling (Polier et al., 2012).
Addition of Roc-A at 20 nM did not inhibit HCV RNA replication or
protein translation (Fig. S3A & B). Rather, it significantly reduced
HCVcc, HCVpp, CHIKVpp, and dengue virus infection (Fig. S3C–G)
at low nanomolar concentrations. Moreover, pretreatment of PHHs
with Roc-A at non-cytotoxic concentrations also suppressed HCVpp
entry (Fig. 3A). The therapeutic index (TI) of Roc-A is greater than 80
when tested on primary human hepatocytes. Notably, Roc-A treatment
decreased the cell surface expression of PHB1 and 2 (Fig. 2A) and also
decreased PHB1, 2, Ras, and CRaf at the total protein level (Fig. 3B).
Roc-A treatment disrupted the PHB-CRaf interaction in a co-IP experi-
ment (Fig. 3C and D). Finally, Roc-A displayed a half-life of 37 min in a
human liver microsomal stability assay (Fig. S4), suggesting that the
compound has good metabolic stability.
3.6. Roc-A Derivatives Display Improved Therapeutic Index
To obtain compounds that displaymore favorable therapeutic index
towards HCV, we evaluated a set of 32 additional rocaglate derivatives
to ascertain structure-activity relationships (SAR) (Table S1). Interest-
ingly, the natural (−) enantiomer of Roc-A displayed stronger inhibi-
tion on HCV entry than the (+) enantiomer (Fig. 3E). Moreover, the
chiral, racemic version of the natural product aglaroxin C (Udom
Kokpol, 1994) exhibited picomolar half-maximum effective concen-
trations (EC50) towards the JFH-1 genotype 2a infectious virus in
cell culture and a therapeutic index of over 100 (Table 1). Further
analysis indicated that (−)-aglaroxin C is the active enantiomer for
Fig. 3.Roc-A potently inhibitsHCV infection. (A) PHHs seeded in a 48-well platewere treatedwith Roc-A or DMSOand then infected byHCVpp. EC50 andCC50 (50% cytotoxicity dose)were
calculated based on the fitted Sigmoid curves. (B) Huh7.5.1 cells were treated with Roc-A (20 nM) or DMSO for 1, 2, and 3 days. Cellular PHB1, PHB2, CRaf, and Ras were detected byWestern
blotting.Numbers shownbelowWesternblot gel images indicate the relative protein levels quantifiedbyOdyssey imaging system(LI-CORBiosciences). (C–D)Flag-CRaf (F-CRaf) andV5-tagged
PHB1 & 2were co-transfected into 293T cells and then left untreated or treatedwith Roc-A (20 nM) before immunoprecipitationwith anti-Flag antibody. The pulled-down PHB1 & 2 as well as
CRaf were detected by immunoblotting. (E) Different inhibitory profiles of the (+)- and (−)-Roc-A enantiomers on HCVcc infection. (F) A CMV-luciferase reporter construct was transfected
intoHuh7.5.1 cells. 24 h post-transfection each compoundwas added to the cells for 3 h at 2 μM. After removal of the compound, the cellswere further incubated for 24 h followed by luciferase
assay. (G) C10 (racemic aglaroxin C) inhibited HCV infection when added together with the virus. HCVcc-Luc was added to Huh7.5.1 cells at 37 °C and incubated for 3 h. At the indicated time
points, 2 μMof each compound or DMSOwas added into themedia and incubated for 3 h prior to removal. Infected cells were incubated at 37 °C for an additional 48 h prior to luciferase assay
(mean of n= 3; error bars, s.d.). Compound E2 (−)-NH hydroxamate, is a potent translation inhibitor (Rodrigo et al., 2012) and hence appeared to inhibit HCV no matter when added; com-
pound C4 (±)-β-lactone (Lajkiewicz et al., 2014), was added as a negative control as it exerted negligible effect.
1604 S. Liu et al. / EBioMedicine 2 (2015) 1600–1606HCV viral entry inhibition (Table 1). Moreover, these compounds,
even when incubated at 2 μM for 3 h, did not inhibit protein transla-
tion (Fig. 3F). Results from a time-of-addition experiment further
showed that chiral, racemic aglaroxin C displayed maximal anti-Table 1
Evaluation of rocaglate derivatives as HCV viral entry inhibitors.a
Compound Structure EC50
(+) Roc-A N200 μMa
(−) Roc-A
1 μMa
4 nMb
(±) Aglaroxin C
(C10)d
100 nMa
40 pMb
(+)-Aglaroxin C 20 μMa
(−)-Aglaroxin C 200 nMa
a Compounds were incubated with cells for a total of 3 h on Huh7.5.1 cells.
b Compounds were incubated with cells for a total of 48 h on Huh7.5.1 cells.
c Measured using a luciferase reporter gene that was transfected into Huh7.5.1 cells. The co
d Name appearing in Fig. 3G.HCV activity when added together with the virus but lost its activity
when added 3 h after the infection was initiated (Fig. 3G). This find-
ing bolstered the notion that aglaroxin C is specifically inhibiting
viral entry.CC50 TI (CC50/EC50) Translation inhibition at 2 μMc
300 μMa N/A No
50 μMa
300 nMb
50a
75b
No
10 μMa
20 nMb
100a
500b
No
100 μMa 5a No
12 μMa 60a No
mpound was added for 3 h.
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The identification of PHB1 and 2 as HCV entry factors is somewhat
surprising because these two proteins are typically recognized as
molecular chaperones that stabilize other mitochondrial proteins. A
fraction of PHB1 and 2 can be found on the surface of Huh7.5.1 cells, al-
though they are not required for the initial binding of virions. Given that
PHB-CRaf interaction is necessary for CRaf activation by Ras (Rajalingam
and Rudel, 2005; Polier et al., 2012), and that HRas is a key host signal
transducer for EGFR-mediated HCV entry (Zona et al., 2013), a plausible
role of PHBs in HCV entry is to link HRas to CRaf-mediated signaling. In
support of this notion, we found that CRaf knockdown reduced HCV in-
fection, as did disruption of PHB-CRaf interaction by Roc-A. PHBs have
been implicated in facilitating signal transduction. For example, a recent
study showed that PHB1, normally stored in mast cell granules, translo-
cates to plasmamembrane lipid rafts upon antigen stimulation in order
to activate the tyrosine kinase Syk-dependent signaling that stimulates
mast cell degranulation and the secretion of cytokines (28).
Exactly when and how HCV activates the PHBs-mediated signaling
remains to be investigated. PHB1/2 do not precipitate with CD81,
SR-BI, CLDN1, or OCLN, but are associated with HCV E2 in both infected
and co-transfected cells. PHBs are anchored to the plasmamembrane or
mitochondrial inner membrane by their transmembrane domains with
carboxyl termini facing cytoplasm or the intermembrane space of mito-
chondria. The C-termini of PHBs recruit CRaf to the inner plasmamem-
brane (Mishra et al., 2005). Given that HCV E2 does not traffic to the
intermembrane space of mitochondria, the interaction between PHBs
and E2 likely takes place in close proximity to the inner plasma mem-
brane although evidence for direct PHB–HCV E2 interaction is still lack-
ing. Since the removal of either the transmembrane domain or C-
terminal domain of PHBs abolishes PHB–E2 interaction, HCV E2 may
form a signaling complex with membrane-bound PHB-CRaf at some
point during entry. The PHBs–HCV E2 associations are not mediated
by cell membranes, as C-terminal deletion of PHBs did not alter their
membrane localization. C-terminal deletion did, however, abolish
PHBs–E2 association. Plasma membrane-bound PHB1 is indispensable
for the activation of CRaf by Ras (Rajalingam and Rudel, 2005;
Rajalingam et al., 2005), and interaction between PHB1 and CRaf re-
quires phosphorylation of PHB1 at Thr 258 and Tyr 259 (Chiu et al.,
2013). Further investigation is needed to understand the topology, the
phosphorylation status of plasmamembrane-bound PHBs, and the like-
ly signaling pathways that PHBs mediate during HCV entry.
An exciting finding of our study is that Roc-A, which binds PHB and
inhibits its interaction with CRaf (Polier et al., 2012), potently inhibited
HCV entry. Roc-A was first reported as an immunosuppressant and in-
hibitor of NF-kappa B activity (31). Roc-A and related rocaglates are
also recognized as potent anticancer compounds (Kim et al., 2006;
Ebada et al., 2011) by inhibiting translation initiation through inhibition
of the RNA helicase eIF4a (Roche et al., 2010a, 2010b; Rodrigo et al.,
2012; Chowdhury et al., 2014; Cencic et al., 2009). Roc-A has also
been shown to indirectly target heat shock factor 1 (HSF1), a multiface-
ted transcriptional regulator of the heat-shock response and numerous
other cellular processes essential for anabolic metabolism, cellular pro-
liferation, and tumorigenesis (Santagata et al., 2013). In the current
study, Roc-A treatment significantly reduced the protein levels of cell
surface-bound PHB1 and PHB2 and disrupted PHB-CRaf interaction,
indicating that it blocks HCV entry by targeting this pathway. The obser-
vation that a racemic, synthetic sample of the natural product aglaroxin
C displays improved therapeutic index relative to enantiopure Roc-A
suggests the possibility for synergy of enantiomers (Zhuang et al.,
2014; Danielsson et al., 2011). In our studies, racemic aglaroxin C did
not inhibit protein translation even at 2 μM over 3 h in a translation in-
hibition assay (Fig. 3F). Future investigations will be needed to under-
stand whether it is possible to selectively target the PHB-CRaf
pathway using appropriately functionalized rocaglates (flavaglines)
and towhat extent theremay be synergy between translation inhibitionor othermechanisms andHCV viral entry effects via PHB's (Cencic et al.,
2010; Rozelle et al., 2014).
In conclusion, the identification of PHB1 and 2 adds additional
targets to the repertoire of HCV entry factors. In contrast to most small
molecule inhibitors that have advanced to the clinic targeting viral com-
ponents, Roc-A, a PHB inhibitor, represents a promising drug lead that
targets a host factor and hence reduces the likelihood that resistance
will be developed. By virtue of its distinct mechanism of inhibition,
Roc-A and its derivatives may also be used in combination with other
anti-HCV drugs for potential synergistic effects in treating HCV infec-
tions, especially in settings where liver cancer is present. The observa-
tion that rocaglates (flavaglines) block CHIKVpp entry (Wintachai
et al., 2015) (Fig. S3F) and dengue virus infection (Fig. S3G) also raises
the hope that Roc-A or an optimized congener may be developed into
a drug curbing infections by the two viruses.
Author contributions
S.L., T.Z., J. A.P., Jr., and T.W. designed the overall project and analyzed
data. S.L., C.Q., J.Z., and T.W. performed most cellular and molecular
experiments. W.W., N.L. and L.E.B. synthesized and curated rocaglate
derivatives. S.L., J. A.P., Jr., and T.W. wrote the manuscript.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.09.018.
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements
This work was supported by grant from National Institute of Health
(NIH R01DK088787 grant to T.W.), by NIH 5P30CA047904-25: HIV-
Associated Malignancies Research (AMC) Supplement (to T.W.), and
by an NIH R01 grant (GM073855, J.A.P, Jr.). Research in the BU-CMD is
supported by NIH grant GM111625. The content is solely the responsi-
bility of the authors and does not necessarily represent the official
views of the National Institute of Health. We thank Ms. Madeline
Weber (Boston University) for assistance with the compound library.
References
Back, J.W., Sanz, M.A., De Jong, L., De Koning, L.J., Nijtmans, L.G., De Koster, C.G., Grivell,
L.A., Van Der Spek, H., Muijsers, A.O., 2002. A structure for the yeast prohibitin
complex: structure prediction and evidence from chemical crosslinking and mass
spectrometry. Protein Sci. 11, 2471–2478.
Bartosch, B., Dubuisson, J., Cosset, F.L., 2003. Infectious hepatitis C virus pseudo-particles
containing functional E1–E2 envelope protein complexes. J. Exp. Med. 197, 633–642.
Cencic, R., Carrier, M., Galicia-Vazquez, G., Bordeleau, M.E., Sukarieh, R., Bourdeau, A.,
Brem, B., Teodoro, J.G., Greger, H., Tremblay, M.L., Porco Jr., J.A., Pelletier, J., 2009. An-
titumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol.
PLoS One 4, e5223.
Cencic, R., Carrier, M., Trnkus, A., Porco Jr., J.A., Minden, M., Pelletier, J., 2010. Synergistic
effect of inhibiting translation initiation in combination with cytotoxic agents in
acute myelogenous leukemia cells. Leuk. Res. 34, 535–541.
Chiu, C.F., Ho, M.Y., Peng, J.M., Hung, S.W., Lee, W.H., Liang, C.M., Liang, S.M., 2013. Raf ac-
tivation by ras and promotion of cellular metastasis require phosphorylation of
prohibitin in the raft domain of the plasma membrane. Oncogene 32, 777–787.
Chowdhury, I., Thompson, W.E., Thomas, K., 2014. Prohibitins role in cellular survival
through Ras-Raf-MEK-ERK pathway. J. Cell. Physiol. 229, 998–1004.
Cormier, E.G., Tsamis, F., Kajumo, F., Durso, R.J., Gardner, J.P., Dragic, T., 2004. CD81 is an
entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 101, 7270–7274.
Danielsson, M., Rosenthal-Aizman, K., Bergsson, G., Unden, A., 2011. Pharmacodynamic
synergy strictly dependent on the co-operative aggregation of enantiomers of cyclic
peptides in the bacterial cell membrane. Bioorg. Med. Chem. Lett. 21, 5262–5265.
Diao, J., Pantua, H., Ngu, H., Komuves, L., Diehl, L., Schaefer, G., Kapadia, S.B., 2012. Hepa-
titis C virus induces epidermal growth factor receptor activation via CD81 binding for
viral internalization and entry. J. Virol. 86, 10935–10949.
Ebada, S.S., Lajkiewicz, N., Porco Jr., J.A., Li-Weber, M., Proksch, P., 2011. Chemistry and bi-
ology of rocaglamides (=flavaglines) and related derivatives from aglaia species
(meliaceae). Prog. Chem. Org. Nat. Prod. 94, 1–58.
Emerson, V., Holtkotte, D., Pfeiffer, T., Wang, I.H., Schnolzer, M., Kempf, T., Bosch, V., 2010.
Identification of the cellular prohibitin 1/prohibitin 2 heterodimer as an interaction
1606 S. Liu et al. / EBioMedicine 2 (2015) 1600–1606partner of the C-terminal cytoplasmic domain of the HIV-1 glycoprotein. J. Virol. 84,
1355–1365.
Evans, M.J., Von Hahn, T., Tscherne, D.M., Syder, A.J., Panis, M., Wolk, B., Hatziioannou, T.,
Mckeating, J.A., Bieniasz, P.D., Rice, C.M., 2007. Claudin-1 is a hepatitis c virus co-
receptor required for a late step in entry. Nature 446, 801–805.
Gerard, B., Sangji, S., O'leary, D.J., Porco Jr., J.A., 2006. Enantioselective photocycloaddition
mediated by chiral bronsted acids: asymmetric synthesis of the rocaglamides. J. Am.
Chem. Soc. 128, 7754–7755.
Hsu, M., Zhang, J., Flint, M., Logvinoff, C., Cheng-Mayer, C., Rice, C.M., Mckeating, J.A., 2003.
Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped ret-
roviral particles. Proc. Natl. Acad. Sci. U. S. A. 100, 7271–7276.
Kato, T., Date, T., Miyamoto, M., Zhao, Z., Mizokami, M., Wakita, T., 2005. Nonhepatic cell
lines hela and 293 support efficient replication of the hepatitis C virus genotype 2a
subgenomic replicon. J. Virol. 79, 592–596.
KimDo, K., Kim, H.S., Kim, A.R., Jang, G.H., Kim, H.W., Park, Y.H., Kim, B., Park, Y.M., Beaven,
M.A., Kim, Y.M., Choi, W.S., 2013. The scaffold protein prohibitin is required for
antigen-stimulated signaling in mast cells. Sci. Signal. 6, ra80.
Kim, S., Salim, A.A., Swanson, S.M., Kinghorn, A.D., 2006. Potential of
cyclopenta[b]benzofurans from aglaia species in cancer chemotherapy. Anti Cancer
Agents Med. Chem. 6, 319–345.
Kolonin, M.G., Saha, P.K., Chan, L., Pasqualini, R., Arap, W., 2004. Reversal of obesity by
targeted ablation of adipose tissue. Nat. Med. 10, 625–632.
Kontorinis, N., Agarwal, K., Dieterich, D.T., 2004. Current status of the use of growth fac-
tors and other adjuvantmedications in patients receiving peginterferon and ribavirin.
Rev. Gastroenterol. Disord. 4 (Suppl. 1), S39–S47.
Kuadkitkan, A., Wikan, N., Fongsaran, C., Smith, D.R., 2010. Identification and characteri-
zation of prohibitin as a receptor protein mediating DENV-2 entry into insect cells.
Virology 406, 149–161.
Lajkiewicz, N.J., Cognetta 3rd, A.B., Niphakis, M.J., Cravatt, B.F., Porco, J.A., 2014. JR, Remod-
eling natural products: chemistry and serine hydrolase activity of a rocaglate-derived
beta-lactone. J. Am. Chem. Soc. 136, 2659–2664.
Lan, J.F., Li, X.C., Sun, J.J., Gong, J., Wang, X.W., Shi, X.Z., Shi, L.J., Weng, Y.D., Zhao, X.F.,
Wang, J.X., 2013. Prohibitin Interacts with envelope proteins of white spot syndrome
virus and prevents infection in the red swamp crayfish, procambarus clarkii. J. Virol.
87, 12756–12765.
Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama,
T., Hynes, R.O., Burton, D.R., Mckeating, J.A., Rice, C.M., 2005. Complete replication of
hepatitis C virus in cell culture. Science 309, 623–626.
Liu, S., Yang, W., Shen, L., Turner, J.R., Coyne, C.B., Wang, T., 2009. Tight junction proteins
claudin-1 and occludin control hepatitis C Virus entry and are downregulated during
infection to prevent superinfection. J. Virol. 83, 2011–2014.
Lupberger, J., Zeisel, M.B., Xiao, F., Thumann, C., Fofana, I., Zona, L., Davis, C., Mee, C.J.,
Turek, M., Gorke, S., Royer, C., Fischer, B., Zahid, M.N., Lavillette, D., Fresquet, J.,
Cosset, F.L., Rothenberg, S.M., Pietschmann, T., Patel, A.H., Pessaux, P., Doffoel, M.,
Raffelsberger, W., Poch, O., Mckeating, J.A., Brino, L., Baumert, T.F., 2011. EGFR and
EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral
therapy. Nat. Med. 17, 589–595.
Mcclung, J.K., Danner, D.B., Stewart, D.A., Smith, J.R., Schneider, E.L., Lumpkin, C.K.,
Dell'orco, R.T., Nuell, M.J., 1989. Isolation of a cDNA that hybrid selects antiprolifera-
tive mRNA from rat liver. Biochem. Biophys. Res. Commun. 164, 1316–1322.
Meertens, L., Bertaux, C., Dragic, T., 2006. Hepatitis C virus entry requires a critical
postinternalization step and delivery to early endosomes via clathrin-coated vesicles.
J. Virol. 80, 11571–11578.
Mishra, S., Murphy, L.C., Nyomba, B.L., Murphy, L.J., 2005. Prohibitin: a potential target for
new therapeutics. Trends Mol. Med. 11, 192–197.
Montano, M.M., Ekena, K., Delage-Mourroux, R., Chang, W., Martini, P., Katzenellenbogen,
B.S., 1999. An estrogen receptor-selective coregulator that potentiates the effectiveness
of antiestrogens and represses the activity of estrogens. Proc. Natl. Acad. Sci. U. S. A. 96,
6947–6952.
Pawlotsky, J.M., Feld, J.J., Zeuzem, S., Hoofnagle, J.H., 2015. From non-A, non-B hepatitis to
hepatitis C virus cure. J. Hepatol. 62, S87–S99.
Petracca, R., Falugi, F., Galli, G., Norais, N., Rosa, D., Campagnoli, S., Burgio, V., Di Stasio, E.,
Giardina, B., Houghton, M., Abrignani, S., Grandi, G., 2000. Structure-function analysis
of hepatitis C virus envelope-CD81 binding. J. Virol. 74, 4824–4830.
Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., Weiner, A.J.,
Houghton, M., Rosa, D., Grandi, G., Abrignani, S., 1998. Binding of hepatitis C virus
to CD81. Science 282, 938–941.
Ploss, A., Evans, M.J., Gaysinskaya, V.A., Panis, M., You, H., De Jong, Y.P., Rice, C.M., 2009.
Human occludin is a hepatitis C virus entry factor required for infection of mouse
cells. Nature 457, 882–886.Polier, G., Neumann, J., Thuaud, F., Ribeiro, N., Gelhaus, C., Schmidt, H., Giaisi, M.,
Kohler, R., Muller, W.W., Proksch, P., Leippe, M., Janssen, O., Desaubry, L., Krammer,
P.H., Li-Weber, M., 2012. The natural anticancer compounds rocaglamides inhibit the
Raf-MEK-ERK pathway by targeting prohibitin 1 and 2. Chem. Biol. 19, 1093–1104.
Rajalingam, K., Rudel, T., 2005. Ras–Raf signaling needs prohibitin. Cell Cycle 4,
1503–1505.
Rajalingam, K., Wunder, C., Brinkmann, V., Churin, Y., Hekman, M., Sievers, C., Rapp, U.R.,
Rudel, T., 2005. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and
epithelial cell migration. Nat. Cell Biol. 7, 837–843.
Roche, S.P., C.,R., Pelletier, J., Porco Jr., J.A., 2010a. Biomimetic photocycloaddition of 3-
hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of
eukaryotic translation. Angew. Chem. Int. Ed. 49, 6338–‐6533.
Roche, S.P., Cencic, R., Pelletier, J., Porco Jr., J.A., 2010b. Biomimetic photocycloaddition of
3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of
eukaryotic translation. Angew. Chem. 49, 6533–6538.
Rodrigo, C.M., Cencic, R., Roche, S.P., Pelletier, J., Porco, J.A., 2012. Synthesis of rocaglamide
hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic
and biological studies. J. Med. Chem. 55, 558–562.
Rozelle, D.K., Filone, C.M., Kedersha, N., Connor, J.H., 2014. Activation of stress response
pathways promotes formation of antiviral granules and restricts virus replication.
Mol. Cell. Biol. 34, 2003–2016.
Sainz Jr., B., Barretto, N., Martin, D.N., Hiraga, N., Imamura, M., Hussain, S., Marsh, K.A., Yu,
X., Chayama, K., Alrefai,W.A., Uprichard, S.L., 2012. Identification of the Niemann-Pick
C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat.
Med. 18, 281–285.
Santagata, S., Mendillo, M.L., Tang, Y.C., Subramanian, A., Perley, C.C., Roche, S.P., Wong, B.,
Narayan, R., Kwon, H., Koeva, M., Amon, A., Golub, T.R., Porco Jr., J.A., Whitesell, L.,
Lindquist, S., 2013. Tight coordination of protein translation and HSF1 activation sup-
ports the anabolic malignant state. Science 341, 1238303.
Scarselli, E., Ansuini, H., Cerino, R., Roccasecca, R.M., Acali, S., Filocamo, G., Traboni, C.,
Nicosia, A., Cortese, R., Vitelli, A., 2002. The human scavenger receptor class B type I
is a novel candidate receptor for the hepatitis C virus. EMBO J. 21, 5017–5025.
Selby, M.J., Glazer, E., Masiarz, F., Houghton, M., 1994. Complex processing and protein:
protein interactions in the E2:NS2 region of HCV. Virology 204, 114–122.
Si, Y., Liu, S., Liu, X., Jacobs, J.L., Cheng, M., Niu, Y., Jin, Q., Wang, T., Yang, W., 2012. A human
claudin-1-derived peptide inhibits hepatitis C virus entry. Hepatology 56, 507–515.
Stone, S.D., Lajkiewicz, N.J., Whitesell, L., Hilmy, A., Porco Jr., J.A., 2015. Biomimetic kinetic
resolution: highly enantio- and diastereoselective transfer hydrogenation of aglain
ketones to access flavagline natural products. J. Am. Chem. Soc. 137, 525–530.
Theiss, A.L., Sitaraman, S.V., 2011. The role and therapeutic potential of prohibitin in dis-
ease. Biochim. Biophys. Acta 1813, 1137–1143.
Udom Kokpol, B.V., Simpson, J., Weavers, R.T., 1994. Isolation and X-ray structure deter-
mination of a novel pyrimidinone from Aglaia odorata. J. Chem. Soc. Chem. Commun.
773–774.
Wintachai, P., Thuaud, F., Basmadjian, C., Roytrakul, S., Ubol, S., Desaubry, L., Smith, D.R.,
2015. Assessment of flavaglines as potential chikungunya virus entry inhibitors.
Microbiol. Immunol. 59, 129–141.
Wintachai, P., Wikan, N., Kuadkitkan, A., Jaimipuk, T., Ubol, S., Pulmanausahakul, R.,
Auewarakul, P., Kasinrerk, W., Weng, W.Y., Panyasrivanit, M., Paemanee, A.,
Kittisenachai, S., Roytrakul, S., Smith, D.R., 2012. Identification of prohibitin as a
chikungunya virus receptor protein. J. Med. Virol. 84, 1757–1770.
Yang, W., Qiu, C., Biswas, N., Jin, J., Watkins, S.C., Montelaro, R.C., Coyne, C.B., Wang, T.,
2008. Correlation of the tight junction-like distribution of claudin-1 to the cellular
tropism of HCV. J. Biol. Chem. 283 (13), 8643–8653.
Zhang, J., Randall, G., Higginbottom, A., Monk, P., Rice, C.M., Mckeating, J.A., 2004. CD81 is
required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78,
1448–1455.
Zhuang, C., Sheng, C., Shin, W.S., Wu, Y., Li, J., Yao, J., Dong, G., Zhang, W., Sham, Y.Y., Miao,
Z., 2014. A novel drug discovery strategy: mechanistic investigation of an enantio-
meric antitumor agent targeting dual p53 and NF-kappaB pathways. Oncotarget 5,
10830–10839.
Zona, L., Lupberger, J., Sidahmed-Adrar, N., Thumann, C., Harris, H.J., Barnes, A., Florentin,
J., Tawar, R.G., Xiao, F., Turek, M., Durand, S.C., Duong, F.H., Heim, M.H., Cosset, F.L.,
Hirsch, I., Samuel, D., Brino, L., Zeisel, M.B., Le Naour, F., Mckeating, J.A., Baumert,
T.F., 2013. HRas signal transduction promotes hepatitis C virus cell entry by triggering
assembly of the host tetraspanin receptor complex. Cell Host Microbe 13, 302–313.
